ReviewAnnals of hematology1994
P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.
Review in Annals of hematology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 60 citations in OpenAlex.
- Immunosuppressive interactions among calcium channel antagonists and selected corticosteroids and macrolides using human whole blood lymphocytes.Drug metabolism and pharmacokinetics · 2004Trial
- Trial
- Interleukin-1 receptor-associated kinase 1 controls chemoresistance and immuno-killing in non-small cell lung cancer.Signal transduction and targeted therapy · 2026Article
- Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells.Scientific reports · 2019Article
- Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.Oncotarget · 2018Article
- Aldehyde dehydrogenase 2 in aplastic anemia, Fanconi anemia and hematopoietic stem cells.Molecular genetics and metabolism · 2016Review
- Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study.Clinical orthopaedics and related research · 2013Article
- Nanoparticles: a promising modality in the treatment of sarcomas.Pharmaceutical research · 2011Review
- Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.Investigational new drugs · 2010Article
- Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma.PloS one · 2010Article
- Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides.Nucleic acids research · 2004Article
- Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action.Clinical microbiology reviews · 1999Review
- Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival.Surgery today · 1999Article
- Classical multidrug resistance in acute myeloid leukaemia.Medical oncology (Northwood, London, England) · 1997Review
- Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.British journal of cancer · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The multidrug transporter, P-glycoprotein (P-gp), is expressed by CD34-positive bone marrow cells, which include hematopoietic stem cells, and in other cells in the bone marrow and peripheral blood, including some lymphoid cells. Multidrug resistance mediated by P-gp appears to be a major impediment to successful treatment of acute myeloid leukemias and multiple myelomas. However, the impact of P-gp expression on prognosis has to be confirmed in several other hematopoietic neoplasms. The role of P-gp in normal and malignant hematopoiesis and clinical attempts to circumvent multidrug resistance in hematopoietic malignancies are reviewed. The recent transduction of the MDR1 gene into murine hematopoietic cells, which protects them from toxic effects of chemotherapy, suggests that MDR1 gene therapy may help prevent myelosuppression following chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.